Timely Treatment

The Hidden Value in PCC’s Medication Access Programs

by Dr. Veronica X. Vela, Senior Director for Healthcare Access

Medbank is one of the county’s and PCC’s very favorite leveraged resources example because it is so extreme. In FY26, PCC secured $9.5 million dollars worth of brand-name medications from a mere $357K investment in staffing and operating costs. What is even more astonishing is that this impressive return on investment is an undercount because it doesn’t capture an additional layer of value: active patient management. Nearly 900 patients participated in the program. Each patient, on average, received four medications with an average annual total cost of approximately $10,000.

Accessing medication through Montgomery Cares

There are two primary ways Montgomery Cares patients access the prescription medications: Community Pharmacy and Medbank. Community Pharmacy offers prescription dispensing for select generic drugs, diabetes management supplies, and vaccines at partner health centers. PCC operates this bulk-purchasing program and buys these generic medications, supplies, and vaccines at discounted rates and ships them directly to Montgomery Cares partner sites. This enables medication dispensing directly at the point of care, with no additional trips to the pharmacy. For patients who rely on public transportation, point-of-care dispensing removes a critical barrier to filling a prescription. 

“The catch is that each drug assistance program has slightly different—and potentially changing—requirements. Understanding them is literally a full-time job.”

Medbank supports those patients whose conditions are best managed by brand-name prescription drugs. These medications would be prohibitively expensive for both the individual patients and the Montgomery Cares healthcare safety-net system, but Pharmaceutical Assistance Programs (PAPs) offered by many pharmaceutical companies put them within reach. The catch is that each drug assistance program has slightly different—and potentially changing—requirements. Understanding them and facilitating the application process is literally a full-time job. That’s where Medbank comes in. 

PCC program staff keep abreast of the application requirements and support patients through the process. They’ve improved the system further by providing updated guidance to referring medical providers on the eligibility criteria for common brand-name drug assistance programs so providers can consider those when making prescribing decisions. If a patient cannot qualify—some programs, for instance, require that applicants be US citizens—the patient and provider can proactively select another drug option for which the patient might qualify, getting the patient to a medication solution more quickly. Once a patient’s application is approved, PAPs deliver monthly prescription fulfillments to the patient’s health center for pickup, similar to the experience with Community Pharmacy. 

Getting ahead of access challenges

The Medbank team worked hard in FY25 to update medication availability guidance for providers to avoid the delays caused by mismatches between patients and PAP program requirements. The team also solved another potential roadblock patients may face, even after years of successful PAP support: the transition to generic availability. 

For example, Humira (adalimumab) is a prescription biologic medication that treats autoimmune diseases and is now available as generic. Established patients who are receiving the medication through Medbank will continue receiving it until the end of their PAP enrollment. At that point, the patient and their provider will have to either switch to a generic version through Community Pharmacy or find another medication available through a PAP for which to apply, with Medbank support. To make this process smooth, the Medbank team sends alerts on availability changes so patients and providers are not surprised at the end of the enrollment period. Hopefully, they have had enough warning to put a new plan in place and avoid any medication disruptions. 

Accelerating patient impact

Getting access to medication in a timely manner is not an outcome calculated into basic return on investment calculations, but it can be critical for patients. Consider the Humira example. This medication is designed to treat autoimmune disorders that can have debilitating effects on patients. Going without medication is not just a matter of discomfort. It can be the difference between relatively normal functioning and noticeable disability. Further, significant interruptions in treatment can cause a person’s immune system to develop antibodies against it, causing Humira to lose its effectiveness even after taking it again. Coordinating transitions between medications and medicine access patients is critical and can be lifesaving.

“Going without medication is not just a matter of discomfort. It can be the difference between relatively normal functioning and noticeable disability.”

We don’t often report on this time-to-treat factor because it is hard to monitor across patients and drug classes, but it is an impact that matters. So, next time we celebrate the financial return on investment for a program like Medbank, remember that even that calculation is underselling the service’s value. There’s the straightforward comparison of dollars spent on staffing and operations versus the dollar value of medication received. Then there’s the leverage you can’t put a dollar sign on: providers with more time to actually care for people, and patients who get relief sooner.  


This article has not been reviewed or approved by the Montgomery County Department of Health and Human Services.

Previous
Previous

Soliciting Partners, Not Dollars

Next
Next

Planning Small